SER 150

Drug Profile

SER 150

Alternative Names: EV 077; EV-077-3201-2; EV-077-3201-2TB; EV-077-3201-2TBS; SER 150 DN; SER 150 TBS

Latest Information Update: 04 Feb 2017

Price : $50

At a glance

  • Originator Evolva Biotech
  • Developer Evolva Holding SA; Serodus
  • Class Anticoagulants; Antivirals; Small molecules
  • Mechanism of Action Platelet aggregation inhibitors; Thromboxane receptor antagonists; Thromboxane synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Diabetic nephropathies
  • No development reported Influenza A virus infections

Most Recent Events

  • 21 Dec 2016 Serodus completes a phase II trial in Diabetic nephropathies in Germany (PO) (EudraCT2014-003985-25)
  • 28 Nov 2016 SER 150 is still available for licensing (http://www.serodus.com)
  • 28 Nov 2016 Serodus completes enrolment in its phase IIa trial for Diabetic nephropathies in Germany
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top